In Brief: Medical Developments International, Ventracor, Anadis, Ozgen, GlaxoSmithKline
Thursday, 14 July, 2005
Chris Weaver has resigned as Medical Developments Internationa (ASX:MVP) managing director and CEO to take up an executive management position with a bank. Current CFO Jeremy Payling will act as interim CEO while the company searches for a new CEO. Payling has also been appointed to the newly created position of chief operating officer. Former AusBiotech head Tony Coulepis has been appointed as a director.
Jane Wilder, former company secretary and corporate solicitor for Tempo Services, will replace Bernadette Kerrigan as Ventracor's (ASX:VCR) company secretary and legal counsel.
Anadi (ASX:ANX) has appointed part-time consultant to the company, Arie Nudel, as a director.
Perth-based GM mouse supplier Ozgene has entered into a license agreement with French company Cellectis to use its patent for creating, developing and selling mice relating to mouse knock-ins.
GlaxoSmithKline's anti-thrombotic drug Arixtra has been approved by the European Commission for use in surgical patients at high risk of life-threatening venous blood clots. This follows US FDA approval of the same indication in May. Arixtra is a synthetic form of the natural anti-clotting agent heparin, and Brisbane biopharma Alchemia (ASX:ACL) has an identical, generic molecule ready for launch when GSK's five-year market exclusivity expires next year.
Link between oestrogen and heart health found in women
Scientists found that oestrogen helps increase the ANXA1 protein, and when ANXA1 is missing, the...
Frequent nightmares accelerate aging, increase risk of death
Nghtmares independently predict faster biological aging and earlier mortality — even after...
Cardiac organoids bring hope for treating heart disease
Australian scientists have developed lab-grown, three-dimensional heart tissues known as cardiac...
